BRAF and ameloblastoma: It seems that BRAF inhibitors can have clinical benefits and responses in recurrent and metastatic ameloblastomas and use as neoadjuvant and/or targeted adjuvant therapy to improve the treatment outcome, especially in locally advanced ameloblastomas (21,22).